-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Sodium 2-Amino-9-[(2-hydroxyethoxy)methyl]purin-6-olate
Category | Herpes simplex Virus (HSV) |
CAS | 69657-51-8 |
Description | Sodium 2-Amino-9-[(2-hydroxyethoxy)methyl]purin-6-olate (CAS# 69657-51-8 ) is a useful research chemical. |
Product Information
Synonyms | sodium;2-amino-9-(2-hydroxyethoxymethyl)-6-purinolate; sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate |
IUPAC Name | sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate |
Molecular Weight | 247.19 |
Molecular Formula | C8H10N5O3Na |
Canonical SMILES | C1=NC2=C(N1COCCO)N=C(N=C2[O-])N.[Na+] |
InChI | InChI=1S/C8H11N5O3.Na/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14;/h3,14H,1-2,4H2,(H3,9,11,12,15);/q;+1/p-1 |
InChIKey | RMLUKZWYIKEASN-UHFFFAOYSA-M |
Boiling Point | 613.1 °C at 760 mmHg |
Purity | ≥98% (HPLC) |
Solubility | In vitro: 10 mM in DMSO |
Appearance | Solid powder |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Complexity | 237 |
Exact Mass | 247.06813348 |
In Vitro | Acyclovir Sodium is the sodium salt form of acyclovir, a synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses of the herpesvirus family. After conversion in vivo to the active metabolite acyclovir triphosphate by viral thymidine kinase, acyclovir competitively inhibits viral DNA polymerase by incorporating into the growing viral DNA chain and terminating further polymerization. |
In Vivo | Acyclovir sodium (20 mg/kg; p.o.; three times daily; for 10 d; BALB/c mice) suppresses the development of skin lesions and results in a dissociation between DTH response and antibody production Animal Model: Specific-pathogen-free BALB/c mice (7-week-old) infected with HSV-1 Dosage: 20 mg/kg Administration: Oral administration; three times daily; for 10 days Result: Suppressed the development of skin lesions and resulted in a dissociation between DTH response and antibody production. |
PSA | 122.14000 |
Target | HSV-1: 0.85 μM (IC50) HSV-2: 0.86 μM (IC50) |